Cell Culture News and Research RSS Feed - Cell Culture News and Research

Insilico Medicine, CCARL and Plantbiosis partner to advance research on aging

Insilico Medicine, CCARL and Plantbiosis partner to advance research on aging

Through this unique partnership, the Baltimore-based Insilico Medicine and Lethbridge-based CCARL will provide expertise in aging research and build on the personalized medicine and drug discovery platforms OncoFinder and GeroScope to develop new systems for age-related diseases. [More]
Research breakthroughs may pave way for new drugs to fight against parasitic worm infections

Research breakthroughs may pave way for new drugs to fight against parasitic worm infections

Recent breakthroughs may pave the way for vaccines and new drugs for those infected by parasitic helminths. These flatworms, including tapeworms that cause hydatid diseases and neurocysticercosis, liver flukes, and blood flukes (schistosomes), infect more than 300 million people and cause approximately four million disability-adjusted life years lost due to chronic illness and death each year. [More]
Digoxin drug may be adaptable for ALS treatment, study suggests

Digoxin drug may be adaptable for ALS treatment, study suggests

Digoxin, a medication used in the treatment of heart failure, may be adaptable for the treatment of amyotrophic lateral sclerosis (ALS), a progressive, paralyzing disease, suggests new research at Washington University School of Medicine in St. Louis. [More]
Walnuts may help prevent Alzheimer's disease, study finds

Walnuts may help prevent Alzheimer's disease, study finds

A new animal study published in the Journal of Alzheimer's Disease indicates that a diet including walnuts may have a beneficial effect in reducing the risk, delaying the onset, slowing the progression of, or preventing Alzheimer's disease. [More]

Finesse Solutions announces launch of SmartVessel for cell culture applications

Finesse Solutions, Inc, Santa Clara, CA, a manufacturer of measurement and control solutions for life sciences process applications, announced the launch of beta testing of SmartVessel, a single-use 3 liter bioreactor vessel with integrated single-use sensors for cell culture applications of mammalian cells, stem cells, insect cells, and plant cells. [More]
HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear today announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. [More]
Researchers are developing compounds to combat causative agents of periodontitis

Researchers are developing compounds to combat causative agents of periodontitis

A total 12 million Germans suffer from periodontitis. If the inflammation remains untreated, this could lead to tooth loss. However, it is also suspected of triggering many other diseases, like cardiopulmonary diseases. Researchers are studying the interactions, and developing compounds to combat the causative agents. [More]
Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment. [More]
Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab. [More]
New finding could accelerate research to regenerate damaged tissue

New finding could accelerate research to regenerate damaged tissue

Scientists at NYU Langone Medical Center have found a way to boost dramatically the efficiency of the process for turning adult cells into so-called pluripotent stem cells by combining three well-known compounds, including vitamin C. [More]
Study suggests potential treatment for cardiovascular disease in people with apoE4 gene variant

Study suggests potential treatment for cardiovascular disease in people with apoE4 gene variant

Researchers at UT-Southwestern Medical Center have found that the most common variant of the circulating protein apolipoprotein E, called apoE3, helps repair the lining of blood vessels. Individuals with another variant, called apoE4, do not get the benefit of this repair, putting them at higher risk for cardiovascular disease. [More]
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Scientists apply iPS cell technology to Huntington's disease transgenic monkey model

Scientists apply iPS cell technology to Huntington's disease transgenic monkey model

Creating induced pluripotent stem cells or iPS cells allows researchers to establish "disease in a dish" models of conditions ranging from Alzheimer's disease to diabetes. [More]
Findings may help develop biomarkers to identify HIV patients at risk of dementia

Findings may help develop biomarkers to identify HIV patients at risk of dementia

Since the introduction of the combination anti-retroviral therapy (cART) in the mid-90s, the life expectancy of HIV patients has significantly improved. As a result, long-term complications are becoming more relevant: almost every second HIV patient is affected by neurocognitive disorders, which can lead to dementia. [More]
Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. [More]
Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola virus up to 5 days after infection, at a time when the disease is severe. [More]
Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol. [More]
Research report: Orphan Diseases Partnering Terms and Agreements

Research report: Orphan Diseases Partnering Terms and Agreements

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies. [More]
Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). [More]
Scientists find that DNA repair drug could help treat leukaemia, other cancers

Scientists find that DNA repair drug could help treat leukaemia, other cancers

A team of scientists led by Research Associate Professor Motomi Osato and Professor Yoshiaki Ito from the Cancer Science Institute of Singapore at the National University of Singapore found that a drug originally designed for killing a limited type of cancer cells with DNA repair defects could potentially be used to treat leukaemia and other cancers. [More]